Having trouble accessing articles? Reset your cache.

Onbrez Breezhaler indacaterol: Phase III data

In the double-blind, international Phase III INSIST trial in 1,123 patients ages 40 and older, 150 µg once-daily indacaterol was superior to 50 µg twice-daily salmeterol on the primary endpoint of significantly improving FEV1 AUC from 5 minutes to

Read the full 397 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers